Karyopharm Therapeutics (KPTI) Misses Q1 EPS by 1c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($0.75), $0.01 worse than the analyst estimate of ($0.74).

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Academy Sports and Outdoor (ASO) Tops Q2 EPS by 22c, Offers Guidance
• Sunbelt Rentals Holdings, Inc. (SUNB) Reports Q2 EPS of $1.18
• Core & Main, Inc (CNM) Tops Q3 EPS by 2c ; Offers Guidance